Pulmonary Embolism — Diagnosis & Treatment

Key Points

• Use a validated pretest-probability approach before ordering D-dimer or CT imaging.
• PERC can avoid testing only in appropriately selected very low-risk patients.
• Use age-adjusted D-dimer in suitable adults over 50 to improve specificity.
• CT pulmonary angiography is the usual definitive test; V/Q scanning and leg ultrasound are important alternatives in selected patients.
• Shock or persistent hypotension from PE requires urgent reperfusion assessment, not anticoagulation alone.
• Stable patients with RV strain or positive biomarkers need risk-stratified monitoring rather than routine lysis.
• Choice of anticoagulant depends on hemodynamics, renal function, pregnancy, cancer, drug interactions, bleeding risk, and possible procedures.
• At least 3 months of anticoagulation is standard for acute PE unless a major contraindication changes the plan.

Algorithm

1. Assess hemodynamic stability and immediately treat shock, hypoxemia, or cardiac arrest.
2. Estimate pretest probability using clinical gestalt or a validated score; apply PERC only when probability is very low.
3. Use D-dimer for low or intermediate probability and proceed to imaging when positive; bypass D-dimer when probability is high.
4. Obtain CTPA, or use V/Q scanning or proximal compression ultrasound when clinically appropriate.
5. Once PE is confirmed, classify risk using blood pressure, RV assessment, biomarkers, oxygenation, and a prognostic score.
6. Start appropriate anticoagulation unless contraindicated; use UFH when rapid procedural flexibility is important.
7. For high-risk PE, activate a multidisciplinary reperfusion pathway and choose systemic thrombolysis, catheter intervention, or surgical embolectomy based on bleeding risk and resources.
8. Determine inpatient versus outpatient management and establish an anticoagulation duration and follow-up plan.

Clinical Synopsis & Reasoning

Pulmonary embolism should be considered in unexplained dyspnea, pleuritic chest pain, hypoxemia, syncope, tachycardia, hemoptysis, or signs of deep vein thrombosis, but presentations are often nonspecific. Begin with clinical probability rather than ordering CT pulmonary angiography for every patient. In very low-risk patients, a validated PERC strategy can avoid testing when all criteria are satisfied. In low or intermediate probability, an age-adjusted D-dimer can reduce unnecessary imaging in older adults. Patients with high clinical probability generally proceed directly to definitive imaging unless instability requires immediate bedside decision making. CT pulmonary angiography is the standard imaging test for most adults. Ventilation-perfusion scanning is useful when iodinated contrast is unsuitable and the chest radiograph is favorable. Compression ultrasound can establish venous thromboembolism when proximal DVT is found in an appropriate clinical context. After PE is diagnosed, determine hemodynamic risk. Sustained hypotension, shock, or cardiac arrest defines a high-risk emergency. In patients without shock, right ventricular dysfunction, cardiac biomarkers, oxygen requirement, comorbidity, and validated prognostic tools help distinguish intermediate from low risk. Bedside echocardiography is particularly useful in unstable patients, but right ventricular strain is not specific for acute PE. Always consider alternative or coexisting diagnoses such as acute coronary syndrome, aortic dissection, pneumonia, pneumothorax, heart failure, and sepsis.

Treatment Strategy & Disposition

Start anticoagulation promptly when PE is confirmed and bleeding risk is acceptable. When clinical probability is high and imaging will be substantially delayed, empiric anticoagulation can be appropriate after individualized bleeding assessment. Direct oral anticoagulants are preferred for many stable patients, while unfractionated heparin is favored when rapid reversal may be needed, renal function is severely impaired, or thrombolysis, thrombectomy, or surgery is being considered. Low-molecular-weight heparin remains useful in pregnancy and selected cancer-associated thrombosis pathways. High-risk PE with shock requires immediate multidisciplinary reperfusion assessment. Systemic thrombolysis is the fastest broadly available reperfusion therapy when there is no prohibitive bleeding risk. Catheter-directed therapy or surgical embolectomy may be chosen when thrombolysis is contraindicated, has failed, or local expertise favors an invasive strategy. Routine thrombolysis is not recommended for hemodynamically stable intermediate-risk PE because major bleeding can outweigh benefit; these patients need close monitoring for decompensation and rescue reperfusion if instability develops. Selected low-risk patients can be managed as outpatients when validated criteria, social support, bleeding risk, oxygenation, and follow-up are favorable. Anticoagulation is generally continued for at least 3 months, with extended therapy based on whether the event was provoked, recurrence risk, bleeding risk, cancer, thrombophilia context, and patient preference.

Epidemiology / Risk Factors

• Venous thromboembolism risk rises with recent surgery or trauma, immobility, active cancer, estrogen exposure, pregnancy and postpartum state, prior VTE, thrombophilia, and increasing age.
• Many PEs arise from proximal lower-extremity DVT, although DVT symptoms may be absent.
• Unprovoked PE has a higher long-term recurrence risk than PE caused by a major transient provoking factor.
• Cancer-associated VTE requires attention to tumor type, bleeding site, thrombocytopenia, drug interactions, and procedures.
• Hospitalized and recently discharged patients remain at increased VTE risk, making prophylaxis and mobility important preventive measures.

Investigations

Initial Anticoagulation Options

Pharmacology

Prognosis / Complications

• Shock, cardiac arrest, severe RV failure, elevated lactate, and persistent hypoxemia identify the highest immediate mortality risk.
• Most hemodynamically stable low-risk patients do well with anticoagulation alone.
• Major bleeding is the principal treatment hazard and must be reassessed throughout anticoagulation.
• Recurrent VTE risk depends on whether the event was provoked, persistent risk factors, cancer, and prior events.
• A minority develop chronic thromboembolic pulmonary hypertension or chronic functional limitation after PE.

Patient Education / Counseling

• Teach bleeding precautions and medication-specific instructions for the chosen anticoagulant, including missed doses and interacting drugs.
• Advise immediate evaluation for recurrent sudden dyspnea, chest pain, syncope, hemoptysis, unilateral leg swelling, or major bleeding.
• Review the planned duration of anticoagulation and explain why it may change after reassessment of provoking factors and bleeding risk.
• Discuss contraception, pregnancy planning, procedures, and long-distance travel when relevant because anticoagulant management may need adjustment.
• Encourage follow-up for persistent breathlessness, exercise intolerance, or edema after the acute event.

Notes

Reperfusion decisions should be driven by hemodynamic risk, not clot size alone. A large clot burden on CT does not by itself mandate thrombolysis, while a smaller embolic burden can still be life threatening if it produces severe RV failure in a vulnerable patient. Conversely, an elevated troponin or RV strain in a normotensive patient does not automatically justify lysis. These intermediate-risk patients benefit from monitored care, rapid access to rescue reperfusion, and repeated assessment for worsening blood pressure, oxygenation, lactate, or RV function. When discharging a low-risk patient, confirm that the anticoagulant can be obtained immediately, dosing is understood, bleeding risk is acceptable, oxygenation and pain are controlled, and follow-up is reliable.

References

1. CHEST Guideline: Antithrombotic Therapy for VTE Disease — Link